erlotinib

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR-Mutant Lung Cancer

Conditions

EGFR-Mutant Lung Cancer

Trial Timeline

Oct 15, 2013 → Nov 8, 2018

NCT ID

NCT01967095

About erlotinib

erlotinib is a phase 1 stage product being developed by Astellas Pharma for EGFR-Mutant Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01967095. Target conditions include EGFR-Mutant Lung Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02770014	Phase 2	Terminated	Jun 1, 2016	Jun 19, 2019	Epidermal Growth Factor Receptor
NCT01967095	Phase 1	Completed	Oct 15, 2013	Nov 8, 2018	EGFR-Mutant Lung Cancer
NCT01573702	Phase 2	Completed	Dec 11, 2012	Mar 15, 2019	Non Small Cell Lung Cancer
NCT01247922	Phase 2	Terminated	May 23, 2011	Sep 13, 2012	Ependymoma
NCT01116336	Phase 1	Completed	Mar 1, 2010	May 1, 2018	Cancer of Head and Neck

Competing Products

2 competing products in EGFR-Mutant Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	52
EGF816 + trametinib + ribociclib + LXH254 + INC280 + gefitinib	Novartis	Phase 1	33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved